Skip to main content

Table 3 Cytokine release and activation/maturation markers after FTY or FTYP in vitro

From: Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation

APC subtype

Cytokine

Without

FTY

p value

FTYP

p value

slanDC

IL-1beta

26,753.7 (+/−13,156.6)

750.8 (+/−277.3)

<0.05

6835.1 (+/−2634.6)

<0.05

 

IL-6

69,634.3 (+/−18,883.2)

7180.5 (+/−1748.1)

<0.05

46,643.9 (+/−8215.2)

<0.05

 

TNF-alpha

18,837.0 (+/−9012.4)

1576.9 (+/−267.4)

<0.05

5960.4 (+/−2131.8)

<0.05

 

IL-12

637.7 (+/−141.8)

92.2 (+/−19.5)

<0.01

312.8 (+/−153.3)

n.s.

 

IL-23

4423.2 (+/−2068.8)

136.9 (+/−29.9)

<0.05

1919.4 (+/−644.6)

<0.05

CD1+ DC

IL-1beta

624.4(+/−282.8)

266.2 (+/−37.1)

<0.05

284.3 (+/−15.7)

<0.05

 

IL-6

6889.3 (+/−1367.2)

1259.1 (+/−91.5)

<0.01

5413.8 (+/−1100.4)

n.s.

 

TNF-alpha

2203.0 (+/−1140.7)

933.9 (+/−387.3)

<0.05

468.6 (+/−37.9)

<0.05

 

IL-12

74.8 (+/−20.5)

66.4 (+/−6.6)

n.s.

66.3 (+/−7.2)

n.s.

 

IL-23

250.7 (+/−36.1)

251.2 (+/−61.7)

n.s.

189.1 (+/−22.9)

n.s.

Monocytes

IL-1beta

8670.9 (+/−4065.2)

4902.8 (+/−1932.1)

<0.05

599.8 (+/−113.4)

<0.05

 

IL-6

105,741.0 (+/−24,004.5)

31,584.8 (+/−11,302.5)

<0.05

32,223.6 (+/−8824.4)

<0.05

 

TNF-alpha

2050.2 (+/−622.3)

1149.2 (+/−345.7)

n.s.

705.1 (+/−164.8)

<0.05

APC subtype

Surface marker

Without

FTY

p value

FTYP

p value

slanDC

CD83

866.6 (+/−88.9)

426.8 (+/−34.5)

<0.05

477.5 (+/−63.7)

<0.05

 

HLADR

243.1 (+/−40,9)

254.7 (+/−56,7)

n.s.

300.0 (+/−73,5)

n.s.

 

CD86

681.6 (+/−115.1)

571.6 (+/−105.9)

n.s.

670.3 (+/−105.4)

n.s.

 

CD80

896.5 (+/−42.3)

812.5 (+/−39.1)

n.s.

906.5 (+/−63.7)

n.s.

 

CD40

510.0 (+/−72.9)

573.4 (+/−100.1)

n.s.

542.5 (+/−90.2)

n.s.

CD1 + DC

CD83

720.9 (+/−135.9)

587.8 (+/−128.7)

n.s.

707.0 (+/−111.3)

n.s.

 

HLADR

405.3 (+/−94.0)

418.0 (+/−63.5)

n.s.

327.4 (+/−75.7)

n.s.

 

CD86

810.8 (+/−189.2)

703.3 (+/−64.8)

n.s.

893.4 (+/−197.2)

n.s.

 

CD80

632.8 (+/−61.7)

588.5 (+/−45.7)

n.s.

601.5 (+/−23.6)

n.s.

 

CD40

556.5 (+/−44.3)

650.0 (+/−75.6)

n.s.

578.6 (+/−50.8)

n.s.

Monocytes

CD150

253.2 (+/−23.8)

80.7 (+/−8.3)

<0.05

106.8 (+/−5.9)

<0.05

 

HLADR

131.1 (+/−17.7)

177.0 (+/−36.5)

n.s.

109.1 (+/−18.5)

n.s.

 

CD86

295.8 (+/−27.0)

352.0 (+/−36.7)

n.s.

243.6 (+/−25.9)

n.s.

 

CD80

165.8 (+/−29.6)

171.3(+/−15.6)

n.s.

162.8 (+/−22.4)

n.s.

 

CD40

395.0 (+/−49.7)

459.5 (+/−58.2)

n.s.

332.1 (+/−47.7)

n.s.

  1. Sorted slanDCs, CD1+ DCs, and monocytes of eight healthy donors were stimulated in the absence (without) or presence of 30 ng/ml FTY or FTYP. Release of pro-inflammatory cytokines and expression of surface maturation/activation markers was then evaluated. Mean values of cytokines in picograms per millliliter or MFI of surface expression are presented, Bonferroni’s correction was used for multiple testing, and p values indicate level of statistical significance
  2. n.s. not significant
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094